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Variants inGBA are associated with Lewy Body (LB) pathology. We investigated whether
variants in other lysosomal storage disorder (LSD) genes also contribute to disease
pathogenesis.
Methods
We performed a genetic analysis of four LSD genes includingGBA, HEXA, SMPD1, and
MCOLN1 in 231 brain autopsies. Brain autopsies included neuropathologically defined LBD
without Alzheimer Disease (AD) changes (n = 59), AD without significant LB pathology (n =
71), Alzheimer disease and lewy body variant (ADLBV) (n = 68), and control brains without
LB or AD neuropathology (n = 33). Sequencing of HEXA, SMPD1,MCOLN1 andGBA fol-
lowed by ‘gene wise’ genetic association analysis was performed. To determine the func-
tional effect, a biochemical analysis ofGBA in a subset of brains was also performed.
GCase activity was measured in a subset of brain samples (n = 64) that included LBD
brains, with or without GBAmutations, and control brains. A lipidomic analysis was also per-
formed in brain autopsies (n = 67) which included LBD (n = 34), ADLBV (n = 3), AD (n = 4),
PD (n = 9) and control brains (n = 17), comparing GBAmutation carriers to non-carriers.
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Results
In a ‘gene-wise’ analysis, variants inGBA, SMPD1 andMCOLN1 were significantly associ-
ated with LB pathology (p range: 0.03–4.14 x10-5). Overall, the mean levels of GCase activi-
ty were significantly lower inGBAmutation carriers compared to non-carriers (p<0.001). A
significant increase and accumulation of several species for the lipid classes, ceramides
and sphingolipids, was observed in LBD brains carryingGBAmutations compared to con-
trols (p range: p<0.05-p<0.01).
Interpretation
Our study indicates that variants inGBA, SMPD1 andMCOLN1 are associated with LB pa-
thology. Biochemical data comparing GBAmutation carrier to non-carriers support these
findings, which have important implications for biomarker development and
therapeutic strategies.
Introduction
Lewy body disorders (LBD) which include Parkinson’s Disease (PD) and Dementia with Lewy
bodies (DLB) are characterized by neuronal loss in the substantia nigra (SN) and the presence
of neuronal cytoplasmic inclusions composed predominantly of α-synuclein termed Lewy
Bodies (LBs)[1–3]. α-synuclein immunoreactivity, including LB, have been described as fea-
tures seen in the neuropathology of several lysosomal storage disorders including notably
Gaucher disease (GD), but also Sandhoff disease, Tay Sachs disease, and Sanfilippo syndrome
[4–8]. Heterozygosity for mutations in the gene encoding glucocerebrosidase (GBA), which
cause Gaucher disease (GD), has been identified as a risk factor for both PD and DLB. We and
others have shown that in sporadic and familial PD, GBAmutations are associated with early-
onset PD and may modify age at onset of PD[9,10] and that in brain autopsies GBAmutation
status was significantly associated with the presence of cortical LB (OR = 6.48, 95% CI, 2.45–
17.16, p<0.001) and a neuropathological diagnosis of DLB after adjusting for sex, age at death,
and presence of APOE-4[11]. A recent study that assessed the association of specific founder
mutations in each of the lysosomal storage disorder genes HEXA, SMPD1 andMCOLN1, in
938 Ashkenazi Jewish (AJ) PD patients and 282 matched AJ controls, reported SMPD1 L302P
as a risk factor for PD in the AJ population[12].
To determine whether variants in other lysosomal storage disease genes, in the same path-
way as GBA, are associated with LBs we conducted an independent genetic study of the lyso-
somal storage disorder genes GBA,HEXA, SMPD1, andMCOLN1 in 231 brain autopsies from
the New York Brain Bank at Columbia University. Brain autopsies included neuropathologi-
cally defined LBD without AD changes (n = 59), AD without significant LB pathology (n = 71),
ADLBV (n = 68), and control brains without LB or AD neuropathology (n = 33). The function-
al effect of GBA mutations was also determined by performing a biochemical analysis of GBA
in a subset of brains.
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Materials and Methods
Clinical material
Brain tissue samples were obtained from the New York Brain Bank at Columbia University in-
cluding cases obtained through the Alzheimer’s Disease Research Center and the Center for
Parkinson’s Disease and Other Movement Disorders. Brain autopsies included neuropatholo-
gically defined LBD without AD changes (n = 59), AD without significant LB pathology
(n = 71), ADLBV (n = 68), and control brains without LB or AD neuropathology (n = 33).
(Table 1 and S1 Table). LB and Alzheimer plaque and tangle pathology was assessed according
to published guidelines as described previously[13–15] (see S1 Methods for a detailed descrip-
tion of neuropathological evaluation). Clinical information on dementia was available for 208
brain autopsy samples (see S1 Methods). While the primary analysis in this paper is of autopsy
proven cases, an additional group of living controls (128 Ashkenazi Jewish (AJ) healthy indi-
viduals were used in a secondary analysis to supplement the limited number of brain autopsy
controls (see S1 Methods for a description of the controls). Columbia University Institutional
Review Board approved the protocols and consent procedures. Written informed consent was
obtained from all participants in the study.
Population Stratification and Ashkenazi Jewish Ancestry
Since a founder effect for LSD gene mutations have been reported in the AJ population we also
determined AJ ancestry in brain autopsy samples. Information about AJ ancestry was not avail-
able for brain autopsies. We used two methods to examine AJ ancestry and underlying popula-
tion structure in brain autopsies. In the first method, Multidimensional scaling (MDS) as
implemented in the program PLINK (Version 1.07) for detecting population outliers and ad-
justing for population stratification was used. Briefly, we used 288, 963 autosomal SNPs for
brain autopsies (n = 62), augmented with 252 AJ samples with subjects from the HapMap web-
site (http:www.hapmap.org/), which included 90 CEU, 90 Yorubans and 90 Asians. The best
fitting model assumed two underlying populations with overlap of 27 white brain autopsies
with the AJ cluster and the remainder of the white brain autopsies with the white CEU cluster.
In the second method, principle component analysis (PCA) as implemented in the GCTA
package [16] was used to examine ancestry and admixture in white brain autopsies, AJ samples
together with subjects from HapMap. Projection of all the sample genotypes along the two
principle components (PC2 and PC3) is shown in S1 Methods. As in the MDS analysis per-
formed in PLINK, there is tight clustering of 27 brain autopsies with AJ sample cluster and the
remainder of the white brain autopsies cluster with CEU samples.
Molecular Genetic Analysis
Frozen cerebellar tissue was used to extract DNA. Sequencing of all GBA exons was performed
as described previously[9]. Sequencing of all exons of HEXA, SMPD1 andMCOLN1 was also
performed. Details of PCR and sequencing primers are available upon request. APOE genotyp-
ing was performed by MALDI-TOF mass spectrometry on the Sequenom platform as de-
scribed previously[11].
Analysis of functional effect of variants
The National Center for Biotechnology information (NCBI), ClinVar, the NHLBI Exome Se-
quencing project (ESP) exome variant server in addition to in silico prediction was used to as-
sess the deleterious effect of variants.
LSD Gene Variants and Risk for LBD
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Enzyme Activity Measurements
For enzyme activity measurements, a subset (n = 64) of the total autopsy sample (n = 231) for
which frozen brain tissue was available was selected based on neuropathological diagnosis and
GBAmutation carrier status (GBAmutation carriers (n = 16), LBD brains without GBAmuta-
tions (n = 18) and control brains (n = 30)). Brain autopsy tissue (Cerebellum, BA4 and BA9
and ScxV) samples were homogenized in water (10% wt./vol.) using a Misonix Sonic Dismem-
brator and centrifuge at 30,000 Xg for 20 min. Protein concentration was determined using the
Lowry method. The reaction mixture for β -glucocerebrosidase determination consisted of
50ug of protein, 50ul of 20mM 4-methylumbelliferyl-β-D-glucopyranoside, 10ul of 1M Cit-
rate-Phosphate pH 5.0 and 10ul of 2% Sodium Tauro Deoxycholate. The reaction mixture was
Table 1. Characteristics of Autopsy Subjects.
All autopsies LBD ADLBV AD Control Total
N 59 68 71 33 231
Male % 71.2 52.9 36.6 54.5 52.8
Age at Dementia (yr) Mean 66.6 67.6 70.7 68.4
SD 10.3 9.6 8.5 9.5
Age at Death (yr) Mean 78.3 79.1 81.6 70.3 78.4
SD 8.7 8.5 8.6 14.2 10.1
Duration (yr) Mean 11.6 10.3 10.0 10.6
SD 6.1 6.1 4.3 5.5
Education (yr) Mean 16.6 14.1 13.8 14.2 14.5
SD 2.3 4.1 4.3 3.4 4.0
Ethnicity % White 94.9 86.8 85.9 60.6 84.8
%AJ ancestry N (individuals) 3 7 15 2 27
% AJ (n/total samples with GWAS) 100(3/3) 35 (7/20) 41.67 (15/36) 66.67 (2/3) 43.5** (27/62)
LB Pathology Present % 100.0 100.0 16.9 3.0 60.6
LB Cortical Pathology Present % 100.0 100.0 0.0 0.0 55.0
LB Subcortical Pathology Present % 64.4 69.1 12.7 0.0 40.7
AD Pathology Present % 79.7 100.0 100.0 33.3 85.3
AD Pathological Diagnosis % 0.0 100.0 100.0 0.0 60.2
GBA mutation N(Individuals) 28 16 6 1 51
% 47.5 23.5 8.5 3.0 22.1
SMPD1 mutation N(Individuals) 12 14 4 3 33
% 20.3 20.6 5.6 9.1 14.3
HEXA mutation N(Individuals) 8 17 8 6 39
% 13.6 25.0 11.3 18.2 16.9
MCOLN1 mutation N(Individuals) 17 20 17 8 62
% 28.8 29.4 23.9 24.2 26.8
APOE (no E4)* N(Individuals) 33 26 26 24 109
% 66.0 41.9 42.6 77.4 47.2
APOE (one E4) * N(Individuals) 13 26 25 6 70
% 26.0 41.9 41.0 19.4 30.3
APOE (two E4) * N(Individuals) 4 10 10 1 25
% 8.0 16.1 16.4 3.2 10.8
* APOE missing in 27cases
**%AJ in brain autopsy sample with GWAS data available (n = 62)
doi:10.1371/journal.pone.0125204.t001
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incubated at 37°C for 2Hours and then subsequently stopped with 2 ml 0.2 M glycine buffer,
pH 10.3. The Hexosamindase A enzymatic reaction mixture consisted of 10ug of protein and
100ul of 3mM 4-methylumbelliferyl-2-acetoamido-2-deoxy-b-D-glucopyranoside in Citrate-
Phosphate buffer pH4.0. Samples were incubated at 37°C for 10min and 0.2M glycine buffer
was also used to stop the reaction. Fluorescence was determined in fluorescence spectropho-
tometer (Hitachi F-2500) at an excitation wavelength of 365 nm and emission wavelength of
448 nm. Samples were compared against a 4-methylumbelliferone (4-MU) standard curve pre-
pared in 0.2 M glycine buffer. Enzyme activities were calculated in nmoles of 4-MU hydro-
lyzed/mg protein/hr. LBD brains did not carry variants in any of the other LSD genes analyzed.
Frozen post-mortem interval (PMI) was available for all autopsy tissue and PMI did not appear
to influence GCase activity.
Lipid Profiling
For lipid profiling, a convenience subset (n = 67) of the total autopsy sample (n = 231) was se-
lected based on neuropathological diagnosis and GBA mutation carrier status that included
LBD brains from GBAmutation carriers (n = 13), LBD brains without GBAmutations
(n = 33), AD brains (n = 4) and control brains (n = 17). Characteristics of the autopsy subjects
are provided in S3 Table. Lipid extracts were prepared using a modified Bligh/Dyer extraction
procedure, spiked with appropriate internal standards. The samples were analysed using an
Agilent 1260 HPLC system coupled to an Agilent 6490 Triple Quadrupole mass spectrometer.
The lipidomic profiles generated for each sample were obtained through a combination of
HPLC separation and mass spectrometry in multiple reactions monitoring mode which allows
for the unambiguous identification of lipids as described previously [17,18]. (S1 Methods).
Statistical Analysis
T tests and chi square tests were used to compare continuous and categorical variables respec-
tively. To determine whether a gene, represented by multiple sequenced variants, is associated
with affection status or not, we applied the sequence kernal association test (SKAT) algorithm
[19]. As above, age and sex were included in one model as covariates, and permutation based
p-value was computed. To determine whether multiple variants in the lysosomal disease genes
are associated with LB pathology in an additive manner, after correcting for age and sex as co-
variates, we applied multiple logistic regression. Although this additive model is simplistic, we
reasoned that this is one way to gain insight into a set of functional (i.e., nonsynonymous) vari-
ants in the common disease pathway.
For lipidomics data, Statistical analysis for the AD and LBD mutation samples was based on
the one way analysis of variance followed by post hoc Fisher’s least significant difference test
while the LBD wild type samples was based on Student’s T-test. In all cases, , p< 0.05; , p
<0.01; , p<0.001.
Results
Demographic and Neuropathological Characteristics of Autopsy
Samples
The basic demographic and neuropathologic information of autopsy samples analysed is
shown in Table 1 (all autopsies, N = 231) and S1 Table (white non-Hispanic ethnicity only,
N = 196). Overall, the proportion of men (71.2%) was higher in the LBD and Alzheimer disease
and lewy body variant (ADLBV) group, compared with that in the AD group (36.6%). Overall,
LBD patients had a significantly earlier age at onset of dementia (66.58±10.28 years vs. 70.71
LSD Gene Variants and Risk for LBD
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±8.46; p = 0.05), earlier age at death (78.26±8.66 years vs. 81.64±8.60; p = 0.04), and had more
years of education (16.61±2.33 years vs. 13.84±4.34; p = 0.02) compared to patients with AD.
APOE4 allele frequencies did not differ from reported population frequencies in non-AD
groups.
Sequencing and Association Analysis: Variants identified and predicted
impact on function
Overall, we identified 51 (22.1%) subjects with a GBA variant, 39 (16.9%) with aHEXA variant,
33 (14.3%) with an SMPD1 variant and 62 (26.8%) with anMCOLN1 variant (Table 1). Many
of the variants that we identified have been reported previously as pathogenic mutations in pa-
tients with the associated lysosomal storage disorder (Table 2). LSD variants that were signifi-
cantly associated in brain autopsies with a neuropathological diagnosis of LBD are shown in
Table 2.
Single GeneWise Association: Multiple variants inGBA, SMPD1 and
MCOLN1 are associated with a neuropathological diagnosis of LBD
SNP-set (Sequence) Kernal Association Test (SKAT) was used to evaluate association of vari-
ants in GBA, HEXA, SMPD1 andMCOLN1 (Table 3). When evaluating all variants, strongest
association was observed for GBA variants in LBD (p = 2.95 x10-5) and ADLBV (p = 3.59 x10-2)
(Table 3). Risk variants inGBA, SMPD1 andMCOLN1 were also significantly associated with
LBD (p range = 0.03–4.14x10-5) and ADLBV (p range = 0.02–0.01) pathology but not AD
(Table 3). We also evaluated association of protective variants and observed association of vari-
ants in SMPD1 in LBD (p = 0.03) and ADLBV (p = 0.02), but not AD, andMCOLN1 variants in
LBD (p = 0.02), ADLBV (p = 0.005) but not AD (Table 3).
The following secondary analyses of the same SKAT models was also performed: 1) SKAT
analysis of LSD variants with MAF<5% in all samples (n = 231)(Table 4), 2) SKAT analysis of
LSD variants with MAF<5% in ‘white’ subjects only (n = 196) (Table 5) and 3) SKAT analysis
of LSD variants in all samples (n = 231) using a larger control group which included the brain
autopsy controls (n = 33) and the AJ controls (n = 128) (S2 Table). When we restricted the
analysis to variants with MAF<5% (Table 4), strongest association was observed for GBA
variants in LBD (p = 1.37x10-4). Risk variants in GBA, SMPD1 andMCOLN1 remained sig-
nificantly associated with LBD (p range = 0.04–1.77x10-4) and ADLBV (p range = 0.04–0.02)
pathology but not AD (Table 4). When we restricted the analysis to whites only with variants
with MAF<5% (Table 5) strongest association was observed for GBA variants in LBD
(p = 0.0118). Risk variants in SMPD1 in ADLBV were also significant (p = 0.0274). Although
not significant, there was a trend towards significance forMCOLN1 risk variants in LBD
(p = 0.189) and ADLBV (p = 0.072). However, the small sample size of the ‘white’ controls
(n = 20) in this stratified analysis may be a confounding factor and the results should be inter-
preted with caution.
SKAT analysis using the larger control group replicated the findings observed using the
brain autopsy controls (n = 33) alone (S2 Table).
Additive Effect of Multiple Variants inGBA, SMPD1 andMCOLN1
In exploratory analyses logistic regression analysis was also used to determine whether multiple
variants in the same disease pathway are associated with disease pathology in an additive man-
ner after adjusting for age and sex as covariates. Strong associations (p range: 0.03–3.8x10-5)
LSD Gene Variants and Risk for LBD
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were also observed for LBD, ADLBV, and AD cases with multiple variants in GBA+SMPD1 or
GBA+SMPD1+MCOLN1 (Table 3).
Table 2. Variants identified in brain autopsy samples.
Gene Chr, genomic
coordinates*




GBA 1:155235002 p.R535H (p.R496H) rs80356773 NA (rare) Pathogenic[20]
1:155235196 p.R502C (p.R463C) rs80356771 NA (rare) Pathogenic[20]
1: 155235252 p.L483P (p.L444P) rs421016 0.0034 Pathogenic[20]
1:155235727 p.D448H (D409H) rs1064651 NA (rare) Pathogenic[20]
1:155235843 p.N409S (N370S) rs76763715 0.0006 Pathogenic[20]
1:155236246 p.T408M (T369M) rs75548401 0.0018 Uncertain significance
1:155236376 p.E365L (p.E326K) rs2230288 0.0050 Pathogenic[20]
1:155237458 p.H294Q (p.H255Q) rs367968666 NA (rare) Pathogenic[20]
1:155238228 p.W223R (p.W184R) rs61748906 NA (rare) Pathogenic[20]
1:155238392 - rs114099990 NA (rare) Unknown
1:155240660–155240661 p.Leu29AlafsX188 (84GG) rs387906315 NA (rare) Pathogenic[20]
1:155236304 p.E388K - NA (rare) Unknown
SMPD1 11:6390654 p.Q19R rs144465428 NA (rare) unknown
11:6390705 p.V36A rs1050228 0.4387 Benign/likely benign
11:6390741–6390742 p.Leu49_Ser50insAL p.
Leu49_Ser50insALAL
rs71056748 NA (rare) Unknown
11:6391701 p.D212D rs7951904 0.1282 Benign/likely benign
11:6392137 p.E358K - NA (rare) Unknown
11:6394233 p.G508R rs1050239 0.15 Benign/likely benign
11:6394336 p.R542L - NA (rare) Unknown
11:6394652 - rs8164 0.1484 Unknown
11:6392136 p.A357A rs72896268 0.0034 Benign/likely benign
11:6391966 p.V301I rs2723669 0.0032 Unknown
11:6390697 p.M33I rs142178073 0.0038 Unknown
11:6394029 p.G492S rs144873307 0.0014 Likely Pathogenic[21]
11:6394261 p.E517V rs142787001 0.0014 Likely Pathogenic[22]
11:6333377 p.R418Q - NA (rare) Unknown
HEXA 15:72347852 - rs2302449 0.0759 Unknown
15:72346579–72346580 p.Y427I (1277_1278insTATC) rs387906309 NA (rare) Pathogenic
15:72349307 - rs73440586 0.0721 Unknown
15:72350564 p.V253V rs117513345 0.0016 Unknown
15:72375964 p.S3S rs1800428 0.0441 Unknown
15:72350584 p.R247W rs121907970 0.0004 Pathogenic
15:72351103 - rs117160567 0.0144 Unknown
15:72345619 - rs2288259 NA (rare) Unknown
15:72346551 p.I436V rs1800431 NA (rare) Benign/likely benign
15:72350518 p.G269S rs121907954 NA (rare) Pathogenic
15:72351103 c.672 +30 T>G rs117160567 0.0144 Unknown[23]
15:72351231 p.V192I - NA (rare) Unknown
15:72355693 - rs10220917 0.0875 Unknown
(Continued)
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GCase activity is decreased in LBDGBAmutation carriers compared to
LBD non-carriers
To determine whether carrier GBAmutation status was associated with reduced enzymatic ac-
tivity (haploinsufficiency) we assayed GCase activity in a subset of autopsy samples (n = 64).
GCase activity was measured in LBD brains from GBAmutation carriers (n = 16), LBD brains
without GBAmutations (n = 18) and control brains (n = 30) (Fig 1) from the following brain
regions Cerebellum, BA4 and BA9 and ScxV.
The enzyme activity of a second lysosomal hydrolase, α-hexosaminidase was also assayed to
demonstrate specificity of decreased activity of GCase. Overall, the mean levels of GCase activi-
ty (p<0.001) and the β-glucocerebrosidase: α -hexosaminidase ratio (p<0.001) were signifi-
cantly lower in GBAmutation carriers compared to non-carriers (Fig 1). We also observed
significant differential enzyme activity of GCase or for the β-glucocerebrosidase:α-hexosamini-
dase ratio in subjects carrying GBAmutations classified phenotypically (as in Gaucher disease)
as ‘severe’ type (e.g. 84insGG, L444P) (p<0.01) compared to subjects carrying GBAmutations
classified phenotypically as ‘mild’ type (e.g. N370S, R496H) (p<0.05) or of unknown pheno-
typic effect (E326K, T369M) (p<0.001) compared to controls (Fig 1). Lastly, we examined the
relation between GCase activity in subjects with a clinical diagnosis of dementia compared to
cases without dementia. Overall, the mean levels of GCase activity (p = 0.0021) and the β-glu-
cocerebrosidase: α -hexosaminidase ratio (p = 0.0014) were significantly lower in cases with de-
mentia than in controls. The pattern of association between GBAmutation status and the
GCase activity was comparable to the combined samples, suggesting that those with dementia








MCOLN1 19:7526723 - rs45513896 0.0222 Unknown
19:7527537 p.P197S rs145706318 NA (rare) Unknown
19:7528162 p.T261M rs73003348 0.0026 Unknown
19:7528283 - rs2305889 0.2821 Unknown
19:7529124 p.C386C rs139922988 0.0004 Unknown
19:7533531 p.G528G rs145386883 0.0006 Unknown
19:7533693 - rs686796 0.0122 Unknown
19:7527954 p.S257R rs113261161 0.0088 Unknown
19:7528685 p.R322R rs61736600 0.0375 Unknown
19:7528703 p.N328N rs612862 0.2556 Unknown
19:7526768 p.A138V rs142259322 0.0008 Unknown
19:7529625 p.S424S rs147754092 0.0012 Unknown
All mutations are described as recommended at www.hgvs.org/mutnomen
*Chr and genomic coordinates as based on assembly GRCh38 and genome build 106.
**Clinical Significance was assessed based on citations (published articles and URLs) documenting the clinical significance or based on pathogenic
status reported in dbSNP or ClinVar
doi:10.1371/journal.pone.0125204.t002
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GBAmutation carriers show significant differences in lipid species and
accumulation of ceramide and sphingolipids
To determine the functional effect of reduced GCase activity in brains with LBs carrying GBA
mutations compared to those without GBAmutations, AD, and control brains we performed a
lipidomic analysis in postmortem brain tissue (n = 67) obtained from the primary motor cortex
(BA4). The a priori hypothesis was that LBD GBAmutation carriers should show significant
differences in ‘specific’ lipid species (substrate and product of GBA hydrolysis) and accumula-
tion of ceramides and sphingolipids compared to those without GBAmutations, AD, and con-
trol brains. Characteristics of autopsy subjects with lipidomic analysis is provided as
supporting data (S3 Table). The cold and frozen PMIs for autopsy tissue used in our analysis is
shown in S4 Table.
Several lipid classes were significantly altered in brains with LBs carrying GBAmutations
compared to controls (P range: p<0.05-p<0.01) (Fig 2 and Fig 3) and this remained significant
after using an false discovery rate (FDR) control to correct for multiple comparisons of lipids
(q<0.05-q<0.01). Major phospholipid subclasses such as phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) were decreased while phosphatidylserine (PS) was increased.
There were also striking changes in sphingolipid composition. A small but significant decline
Table 3. Gene wise association SKAT analysis* in all samples.
Sample size Gene LBD vs. CTRL (n = 59 vs. 33) ADLBV vs. CTRL (n = 68 vs. 33) AD vs. CTRL (n = 71 vs. 33)
P value Marker (n)** P value Marker (n) ** P value Marker (n) **
All variants
GBA 2.95x10-5 11 3.59x10-2 7 0.363 4
SMPD1 0.114 12 0.259 12 0.347 9
HEXA 0.885 9 0.450 13 0.638 7
MCOLN1 3.25x10-2 6 8.31x10-2 11 0.368 9
GBA+SMPD1 2.89x10-4 23 3.94x10-2 19 0.563 13
GBA+SMPD1+MCOLN1 1.29x10-3 29 5.09x10-2 30 0.492 22
Risk variants1
GBA 4.14x-10-5 11 1.27x10-2 6 0.356 4
SMPD1 1.93x10-2 10 6.50x10-2 10 7.68x10-2 5
HEXA 0.124 5 0.105 10 0.254 3
MCOLN1 3.33x10-2 4 2.50x10-2 9 8.78x10-2 7
GBA+SMPD1 3.87x10-5 21 8.35x10-3 16 5.85x10-2 9
GBA+SMPD1+MCOLN1 1.11x10-4 25 4.35x10-3 25 3.39x10-2 16
Protective variants1
GBA -2 1 1 -2
SMPD1 2.80x10-2 2 1.68x10-2 2 0.152 4
HEXA 0.360 4 0.553 3 0.166 4
MCOLN1 2.18x10-2 2 4.89x10-3 2 8.24x10-2 2
GBA+SMPD1 2.76x10-2 2 0.152 3 0.152 4
GBA+SMPD1+MCOLN1 1.79x10-3 4 2.38x10-3 5 4.29x10-2 6
*Corrected for covariates.
** Indicates number of markers included in the test.
1 Risk variants are variants more frequent among cases than controls; whereas, variants are considered protective when they are more frequent in
controls than cases.
2 No protective variants were observed.
doi:10.1371/journal.pone.0125204.t003
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in the most abundant sphingolipid sphingomyelin (SM) was seen in the diseased tissue but was
compensated by increased levels of select dihydrosphingomyelin (dhSM) species and total cer-
amide (Cer) levels. While there was a trend towards an increase in accumulation of the known
GCase substrate, GluCer, the difference was not statistically significant (Fig 2 and Fig 3). How-
ever, the complex glycosphingolipid that is biosynthetically upstream of GluCer, GM3, is high-
ly enriched in these tissues. In addition, there is also a significant accumulation of
galactosylceramide (GalCer) and its biosynthetic derivative sulfatides containing hydroxy fatty
acid (Sulf-OH).
In brains with LBs without GBAmutations, similar changes were observed in major phos-
pholipids PC, PE and PS levels but to a lesser degree compared to those with GBAmutations,
and in the sphingolipids GalCer, Sulf and Sulf-OH. Interestingly LBD brains with and without
GBAmutations displayed an accumulation in lysobisphosphatidic acid LBPA (also known as
bis(monoacylglycero)phosphate), a lipid that is specifically enriched in the late endosome and
lysosome was observed. LBPA also showed a trend for increase in LBD brains with GBAmuta-
tions. To determine the specificity of our assay and also provide a reference point for lipid
changes in the LBD tissue, we also analyzed AD brains and found no significant changes. This
Table 4. Gene wise SKAT analysis of LSD variants with MAF<5% in all samples.
Sample size Gene LBD vs. CTRL (n = 59 vs. 33) ADLBV vs. CTRL (n = 68 vs.
33)
AD vs. CTRL (n = 71 vs. 33)
P value Marker (n)** P value Marker (n) ** P value Marker (n) **
All variants
GBA 1.37 x10-4 11 9.90x10-2 7 0.404 4
SMPD1 0.200 11 0.305 11 0.571 8
HEXA 0.663 7 0.470 10 0.233 5
MCOLN1 6.64x10-2 5 5.45x10-2 9 0.110 6
GBA+SMPD1 4.67 x10-4 22 8.18x10-2 18 0.644 12
GBA+SMPD1+MCOLN1 6.27 x10-4 27 2.94x10-2 27 0.344 18
Risk variants1
GBA 1.77x10-4 11 3.80x10-2 6 0.397 4
SMPD1 2.48x10-2 9 8.36x10-2 9 0.039 4
HEXA 6.82x10-2 4 6.27x10-2 8 0.522 2
MCOLN1 3.91x10-2 4 2.31x10-2 8 4.10x10-2 5
GBA+SMPD1 2.94x10-5 20 1.68x10-2 15 3.46x10-2 8
GBA+SMPD1+MCOLN1 9.07x10-5 24 7.60x10-3 23 1.78x10-2 13
Protective variants1
GBA -2 0.824 1 -2
SMPD1 0.253 2 5.73x10-2 2 0.615 4
HEXA 0.580 3 0.598 2 2.54x10-2 3
MCOLN1 0.373 1 0.810 1 0.448 1
GBA+SMPD1 0.253 2 0.262 3 0.615 4
GBA+SMPD1+MCOLN1 4.99x10-2 3 0.317 4 0.404 5
*Corrected for covariates.
** Indicates number of markers included in the test.
1 Risk variants are variants more frequent among cases than controls; whereas, variants are considered protective when they are more frequent in
controls than cases.
2 No protective variants were observed.
doi:10.1371/journal.pone.0125204.t004
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is in contrast to a previous study [17], although different brain regions were analyzed (i.e., pre-
frontal cortex and entorhinal cortex).
Table 5. Gene wise SKAT analysis of LSD variants with MAF<0.05 in White subjects only.
Sample size Gene LBD vs. CTRL (n = 56 vs. 20) ADLBV vs. CTRL (n = 59 vs.
20)
AD vs. CTRL (n = 61 vs. 20)
P value Marker (n) ** P value Marker (n)** P value Marker (n) **
All variants
GBA 1.18x10-2 10 0.306 7 0.795 4
SMPD1 0.702 9 0.443 10 0.693 7
HEXA 0.912 7 0.770 9 0.177 5
MCOLN1 0.194 4 0.129 8 0.117 5
GBA+SMPD1 3.54x10-2 19 0.205 17 0.853 11
GBA+SMPD1+MCOLN1 2.61x10-2 23 9.97x10-2 25 0.560 16
Risk variants1
GBA 1.02x10-2 10 0.126 6 0.543 3
SMPD1 0.276 8 0.027 7 0.149 4
HEXA 0.209 4 6.55x10-2 6 0.539 2
MCOLN1 0.189 4 7.19x10-2 7 5.86x10-2 4
GBA+SMPD1 7.30x10-3 18 6.60x10-3 13 0.113 7
GBA+SMPD1+MCOLN1 6.30x10-3 22 2.70x10-3 20 3.22x10-2 11
Protective variants1
GBA -2 0.743 1 0.651 1
SMPD1 3.29x10-2 1 0.682 3 0.563 3
HEXA 0.517 3 0.606 3 1.93x10-2 3
MCOLN1 -2 0.794 1 0.826 1
GBA+SMPD1 3.29x10-2 1 0.772 4 0.432 4
GBA+SMPD1+MCOLN1 3.29x10-2 1 0.822 5 0.579 5
*Corrected for covariates.
** Indicates number of markers included in the test.
1 Risk variants are variants more frequent among cases than controls; whereas, variants are considered protective when they are more frequent in
controls than cases.
doi:10.1371/journal.pone.0125204.t005
Fig 1. GCase and HexA activity in autopsy brain tissue. A) GCase activity was significantly reduced in
LBD cases carryingGBAmutations (n = 16) compared to LBD non-GBA carriers (n = 18) and controls
(n = 30). Differences in activity for HEXAwere not significant in any group. B) GCase was significantly
reduced in LBD cases with mutations classified as ‘severe’ type (L444P, 84insGG etc.) compared to controls,
and to LBD cases with ‘mild’ mutations (N370S) or variants of unknown phenotypic effect (E326K, T369M).
Differences in activity for HEXAwere not significant. * p<0.05, ** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0125204.g001
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Discussion
In the current study we performed a genetic analysis of four lysosomal storage disorder genes
including GBA,HEXA, SMPD1,MCOLN1 in 231 brain autopsies from the New York Brain
Bank at Columbia University. A biochemical analysis of GBA was also performed in a subset of
brains. We show that in addition to prior reported variants in GBA, variants in SMPD1 and
MCOLN1 are also significantly associated with LB or ADLBV pathology. Additional gene-wise
analyses for variants based on the SKAT algorithm also identified independent association of
variants in GBA, SMPD1 andMCOLN1 that were significantly associated with LBD and
ADLBV pathologies but not AD. Strong association and an additive effect of multiple variants
in GBA+SMPD1 or GBA+SMPD1+MCOLN1 were also observed across all disease
phenotypes analysed.
The importance of the lysosomal pathway in CNS function and LBD and PD is highlighted
by the identification of genetic risk factors or rare variants/mutations in lysosomal genes in
case-control association studies (GBA and NAGLU)[7,9–11], GWAS studies (LAMP3,
Fig 2. Heat Maps showing significant changes in lipid classes. A) Heat map showing statistically
significant changes in major lipid subclasses in LBDGBAmutation carriers compared to LBD wildtype, AD
cases and controls andB) Heat map showing statistically significant changes in lipid classes in LBDGBA
mutation carriers compared to LBD wildtype, AD cases and controls. The heat map columns reflect all
significant lipid changes (q<0.05) in a diseased compared to control patients. The color bar represents the
log2 value of the ratio of each lipid species. Statistical analysis for the AD and LBDMutation samples was
based on the one way analysis of variance followed by post hoc Fisher’s least significant difference test while
the LBD (wildtype) samples was based on Student’s T-test. A false discovery rate control was used to correct
for multiple comparisons.
doi:10.1371/journal.pone.0125204.g002
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SCARB2)[24,25] or linkage analysis and exome sequencing in PD families (ATP13A2, VPS35
(endolysosomal pathway)[26,27]. A large multisite study of brain autopsy samples from sub-
jects with different forms of dementia identified GBAmutations in 7.6% (6/79) of pure DLB
cases (OR, 7.6 [95% CI, 1.8–31.9]) compared to 3.6% (8/222) of ADLBV cases (OR, 4.6 [95%
CI, 1.2–17.6]) [28].
In our study, multiple variants predicted to be deleterious or damaging in GBA, SMPD1 and
MCOLN1 in autopsy samples were significantly associated with LB and ADLBV pathology. We
identified a total of 26 variants in autopsy samples that have been previously reported as muta-
tions in lysosomal storage disorders. These causal mutations in lysosomal storage disorders are
usually observed in the homozygous or compound heterozygous state whereas in the autopsy
samples that we examined these mutations were observed in the heterozygous state suggesting
that haploinsufficiency of lysosomal genes may contribute to LB and ADLBV phenotype. Over-
all, ~15% of all LBD autopsy samples also carried a variant in more than one lysosomal storage
disease gene examined suggesting that ‘multiple hits’ in the same biochemical pathway, the ly-
sosomal pathway, might increase risk for LBD.
Our data also shows that GBAmutation status is associated with significantly reduced
GCase activity and a neuropathological diagnosis of LBD suggesting that haploinsufficiency or
partial enzyme activity leads to increase in α -synuclein levels and Lewy body pathology. A de-
crease in GCase activity has been reported previously in brain autopsies from patients with
Type I Gaucher Disease and parkinsonism and more recently in brain autopsies from patients
with PD that carry GBAmutations [4,29]. A decrease in GCase activity has also been reported
in brain autopsies from patients with sporadic PD without GBAmutations, with the greatest
reduction in the substantia nigra [29] and conflicting reports of decreased GCase activity in the
frontal cortical regions [29, 30]. In LBD brain autopsy samples from the frontal cortex without
GBAmutations we did not observe a decrease in GCase activity and our findings are consistent
with one published study [29]. These conflicting reports of a reduction in GCase activity in dif-
ferent brain regions from PD or LBD autopsy samples without GBAmutations may reflect dif-
ferent stages of disease progression, neuronal loss or α -synuclein accumulation.
Fig 3. Comparative lipid profile of post-mortem brain tissue obtained from patients diagnosed with
various neurological conditions. Comparative lipid profile of post-mortem brain tissue obtained from
patients diagnosed with various neurological conditions. The individual lipid subclasses of each group of
patients was expressed as relative to control group levels for 2 separate sets of experiments (i.e. AD and LBD
GBAmutation carrier relative to Control S1, LBD non carrier (wildtype) relative to Control S2). Statistical
analysis for the AD and LBDMutation samples was based on the one way analysis of variance followed
by post hoc Fisher’s least significant difference test while the LBD non carrier (wildtype) samples was
based on Student’s T-test. A false discovery rate control was used to correct for multiple comparisons.
* q<0.05, ** q<0.01, *** q<0.001. PC, phosphatidylcholine; ePC, ether phosphatidylcholine; PE,
phosphatidylethanolamine; pPE, plasmalogen phosphatidylethanolamine; PS, phosphatidylserine; PI,
phosphatidylinositol; PA, phosphatidic acid; PG, phosphatidylglycerol; LBPA, lysobisphosphatidic acid;
Cer, ceramide; SM, sphingomyelin; dhSM, dihydrosphingomyelin; GalCer, galactosylceramide; GluCer,
glucosylceramide; Sulf, sulfatide; Sulf-h, hydroxylated sulfatide; GM3, monosialodihexosylganglioside
doi:10.1371/journal.pone.0125204.g003
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We have previously demonstrated the utility of lipidomics as a means to understand dysre-
gulation of lipid metabolism and generate novel insights linked to AD pathogenesis[17]. Ap-
plying similar methodologies to the analysis of the motor cortex region of LBD brains with and
without GBAmutations, we observed that there are significant alterations in both major phos-
pholipid and sphingolipid subclasses compared to controls. In the case of LBD carrying GBA
mutations, GluCer was not significantly accumulated as one might expect. This may be recon-
ciled by the existence of non-lysosomal glucosylceramidase GBA2 that is significantly express-
ed in the brain and can compensate for the deficiency in GBA activity [31, 32]. Nevertheless, it
is worth noting that in both cases of LBD with and without GBAmutation, there appears to be
significant or a trend towards accumulation of other sphingolipid subclasses including Cer,
GalCer, Sulf, Sulf-OH and GM3 and the unusual phospholipid LBPA. LBPA is enriched in late
endosomes where it functions in biogenesis of multivesicular bodies [33] and also in lysosomes
where it plays a role in stimulating the hydrolysis of membrane bound sphingolipids. The over-
all profile of both LBD with and without GBAmutation cases suggests a common theme of dys-
function occurring in the endolysosomal degradative pathway that ultimately lead to defects in
lysosomal clearance of autophagosomes and an accumulation of α -synuclein in LBD.
Recent studies in AD suggest that disease pathogenesis may begin more than 20 years before
the onset of dementia [34]. Similarly in LBD, non-motor symptoms may predate motor symp-
toms by decades suggesting pathophysiological changes before clinical onset [34–37]. To date,
there are no effective biomarkers for LBD. Our study suggests that combined genetic and lipi-
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